Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?
Viruses · 2024
DOI: 10.3390/v16111710 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Giovana Paula Angelice und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil. Hauptthemen laut MEDLINE: Hepatitis B virus, RNA, Small Interfering, RNA Interference. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Oswaldo Cruz, Ministério da Saúde, Brasil, Conselho Nacional de Desenvolvimento Científico, Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Background
Despite an existing safe and effective vaccine for hepatitis B virus (HBV), it is still a major public health concern. Nowadays, several drugs are used to treat chronic hepatitis B; however, full healing remains controversial. The viral covalently closed circular DNA (cccDNA) formed by HBV forms a major challenge in its treatment, as does the ability of HBV to integrate itself into the host genome, which enables infection reactivation. Interfering RNA (RNAi) is a gene-silencing post-transcriptional mechanism which forms as a promising alternative to treat chronic hepatitis B. The aim of the present review is to assess the evolution of hepatitis B treatment approaches based on using RNA interference.
Methods
Data published between 2016 and 2023 in scientific databases (PubMed, PMC, LILACS, and Bireme) were assessed.
Results
In total, 76,949 articles were initially identified and quality-checked, and 226 eligible reports were analyzed in depth. The main genomic targets, delivery systems, and major HBV therapy innovations are discussed in this review. This review reinforces the therapeutic potential of RNAi and identifies the need for conducting further studies to fill the remaining gaps between bench and clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Viral Hepatitis, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.
ORCID-Profile: Pedro Henrique Roque, Livia Melo Villar, Vinicius Motta Mello
Förderung
- Fundação Oswaldo Cruz, Ministério da Saúde, Brasil
- Conselho Nacional de Desenvolvimento Científico
- Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro
Zitieren
APA
Angelice, G. P., Roque, P. H., Valente, G., Galvão, K., Villar, L. M., Mello, V. M., Mello, F. C. A., & Lago, B. V. (2024). Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?. Viruses. https://doi.org/10.3390/v16111710
Vancouver
Angelice GP, Roque PH, Valente G, Galvão K, Villar LM, Mello VM, et al. Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?. Viruses. 2024. doi:10.3390/v16111710
BibTeX
@article{Angelice2024,
author = {Angelice, Giovana Paula and Roque, Pedro Henrique and Valente, Gabriel and Galvão, Krishna and Villar, Livia Melo and Mello, Vinicius Motta and Mello, Francisco C A and Lago, Bárbara Vieira},
title = {Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16111710}
}
EUVIMED